Investigational drug · Phase 2
GNC-035
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed/Refractory Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "GNC-035"
First trial start
2023
Aug 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GNC-035", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- Non-hodgkin's Lymphoma
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "GNC-035" as an intervention, largest first.
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06066203 · 40 participants (planned) · Start Nov 1, 2023 · Primary completion Dec 2026
Drug: GNC-035 · For: Non-hodgkin's Lymphoma
Sites: Beijing, China
- A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast CancerActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05160545 · 36 participants · Start Nov 26, 2021 · Primary completion Dec 2025
Drug: GNC-035 · For: Breast Cancer
Sites: Bengbu, China; Dongguan, China; Guangzhou, China · 6 sites in all
- A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic MalignancyActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05104775 · 33 participants · Start Feb 9, 2022 · Primary completion Dec 2025
Drug: GNC-035 · For: Hematologic Malignancies
Sites: Guangzhou, China; Guiyang, China; Shijiazhuang, China · 7 sites in all
- A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological MalignanciesActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05944978 · 3 participants · Start Aug 16, 2023 · Primary completion Dec 2025
Drug: GNC-035 · For: Relapsed/Refractory Chronic Lymphocytic Leukemia
Sites: Tianjin, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05039931 · 0 participants · Start Sep 15, 2021 · Primary completion Jun 2023
Drug: GNC-035 · For: Breast Cancer; Solid Tumor
Sites: Sichuan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Relapsed/Refractory Chronic Lymphocytic Leukemia
- TQB3909Phase 32 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia, Myeloid Malignancy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.